295 related articles for article (PubMed ID: 11813232)
1. Neuroprotective actions of selegiline.
Ebadi M; Sharma S; Shavali S; El Refaey H
J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232
[TBL] [Abstract][Full Text] [Related]
2. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
4. Selegiline's neuroprotective capacity revisited.
Riederer P; Lachenmayer L
J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
[No Abstract] [Full Text] [Related]
5. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
Knoll J
Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
[TBL] [Abstract][Full Text] [Related]
6. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
Magyar K; Szende B
Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
8. The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research.
Magyar K; Szende B; Lengyel J; Tekes K
J Neural Transm Suppl; 1996; 48():29-43. PubMed ID: 8988460
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective and neuronal rescue effects of selegiline: review.
Magyar K; Haberle D
Neurobiology (Bp); 1999; 7(2):175-90. PubMed ID: 10591051
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
11. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
Gerlach M; Desser H; Youdim MB; Riederer P
J Neural Transm Suppl; 1996; 48():7-21. PubMed ID: 8988458
[TBL] [Abstract][Full Text] [Related]
12. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V
Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
[TBL] [Abstract][Full Text] [Related]
13. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
14. Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
Olanow CW
J Neural Transm Suppl; 1996; 48():75-84. PubMed ID: 8988463
[TBL] [Abstract][Full Text] [Related]
15. Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.
Zhao Q; Cai D; Bai Y
Int J Mol Med; 2013 Oct; 32(4):883-91. PubMed ID: 23877198
[TBL] [Abstract][Full Text] [Related]
16. The multiple actions of selegiline.
Ebadi M; Sharma S; Shavali S; Sangchot P; Brekke L
Proc West Pharmacol Soc; 2002; 45():39-41. PubMed ID: 12434521
[No Abstract] [Full Text] [Related]
17. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Jenner P
Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
[No Abstract] [Full Text] [Related]
18. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
19. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.
Jost WH
J Neural Transm (Vienna); 2022 Jun; 129(5-6):723-736. PubMed ID: 35107654
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotection by selegiline and other MAO inhibitors.
Stern G
J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
